1. Scrip
  2. >>Therapy Areas

Takeda calls time on ramelteon in Europe

 
• By Ian Haydock

Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

A submission for 4mg and 8mg tablets of the melatonin MT1 and MT2 receptor agonist had been made under the centralised procedure in March 2007, for the treatment of primary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.